Durvalumab

Durvalumab is a human monoclonal antibody directed at human programmed death-ligand 1 (PD-L1), a negative regulator of T-cell activity. Durvalumab potentiates T-cell responses, including anti-tumour responses.

What can Sanquin do for you?

Measure drug levels of free drug in the serum using an validated ELISA.
Measure the immunogenicity of durvalumab.
Provide assay reagents or co-develop novel testing strategies.
Folllowing ISO, FDA/EMA, RUO guidelines.

Enquire about our drug level and ADA assays by emailing us at [email protected].

Last edited on: 23 November 2022